At a Glance
- Company: Tenacia Therapeutics; Rapport Therapeutics
- Location: China; United States
- Deal value: Up to 308 million USD (upfront + milestones, plus royalties)
- Focus area: Experimental epilepsy therapy for focal/partial‑onset seizures
- Next steps: China development, regulatory filing and commercial build‑out
What happened?
Tenacia Therapeutics has signed a licensing and development agreement granting it exclusive rights in mainland China to an experimental epilepsy drug from Rapport Therapeutics. The deal is valued at up to 308 million USD in upfront and milestone payments, with additional royalties on net sales. It gives Tenacia control over clinical development, regulatory strategy and commercialisation in its home market while Rapport retains rights elsewhere.
Why does it matter?
China has a large, historically under‑treated epilepsy population, and access to newer, highly targeted CNS agents has lagged behind the US and Europe. By partnering rather than building its own discovery engine, Tenacia can rapidly import a late‑stage, Western‑validated asset, while Rapport gains a capital‑light route into a complex but high‑growth market. The agreement reflects a broader trend of regional CNS deals that localise cutting‑edge neurology drugs for Chinese patients.
Who’s behind it?
Rapport Therapeutics is a clinical‑stage biotech focused on precision neurology, developing small molecules that modulate disease‑relevant neural circuits, with its lead candidate in development for epilepsy. Tenacia Therapeutics operates as a China‑focused specialty pharma company that in‑licenses innovative therapies from global partners and advances them through Chinese trials, registration and launch. Both companies frame the collaboration as a way to leverage complementary strengths in drug creation and local execution.
How was it achieved?
Under the agreement, Tenacia will pay Rapport an upfront fee, followed by development, regulatory and commercial milestones that together can reach roughly 308 million USD, plus tiered royalties on net sales in China. Tenacia takes on the cost and operational responsibility for local trials, interactions with China’s NMPA, and eventual marketing, while Rapport supplies technology transfer, CMC know‑how and access to global data packages. Structurally, the pact mirrors other regional rights deals in which an emerging China player becomes the in‑country “anchor” partner for a single key CNS asset.
What’s next?
Tenacia is expected to initiate or adapt clinical studies to meet Chinese regulatory requirements, with an eye toward bridging from Rapport’s global programme to local approval. Assuming positive outcomes, the company will then build out a neurology‑focused commercial footprint to support launch in major urban centres and epilepsy treatment hubs. For Rapport, the partnership should generate non‑dilutive capital to advance its broader neurology pipeline while creating a future revenue stream from China without needing its own on‑the‑ground infrastructure.